Overview

A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules

Status:
Completed
Trial end date:
2016-07-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.
Phase:
Phase 1
Details
Lead Sponsor:
TenNor Therapeutics (Suzhou) Limited